Stockscreener 앱 받기
157.24
0.79%
-1.26
시장 영업 전:
155.95
-1.29
-0.82%
Astrazeneca Plc 주식(AZN)의 최신 뉴스
AstraZeneca stock holds near $157 after earnings beat - AD HOC NEWS
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? - The Motley Fool
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story? - Yahoo Finance
Sarah Ketterer's Top Q2 2026 Move: AstraZeneca PLC at a 3.92% Po - GuruFocus
AstraZeneca stock holds steady as Q2 2026 earnings beat supports outlook - AD HOC NEWS
Wealthcare Advisory Partners LLC Purchases Shares of 12,112 Astrazeneca Plc $AZN - MarketBeat
AstraZeneca (LSE:AZN) Leads a Defensive Test for UK Blue Chips - Kalkine Media
AstraZeneca slips Wednesday, underperforms market - MarketWatch
AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Combo Gets Approval in China - marketscreener.com
Daiichi, AstraZeneca drug Enhertu wins further approval in China - marketscreener.com
AstraZeneca (LSE:AZN) And GSK (LSE:GSK) Shift Blue-Chip Attention To Drug Pipelines - Kalkine Media
AstraZeneca (LSE:AZN) Puts Innovation At The Centre Of Blue-Chip Healthcare - Kalkine Media
How AstraZeneca’s $400bn deal unravelled - Financial Times
AstraZeneca PLC (Dinari Tokenized Stock) (AZN) Price Prediction for 2026 to 2031 - Bybit
AstraZeneca and Bristol-Myers Squibb's $401.9 Billion Merger Collapses in Abrupt Boardroom Reversal - finance.biggo.com
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk - Yahoo Finance
AstraZeneca held talks with Bristol-Myers through spring, summerFT - Seeking Alpha
Do Options Traders Know Something About AstraZeneca Stock We Don't? - Yahoo Finance
Hedge Funds are Bullish on AstraZeneca PLC (AZN) - Yahoo Finance
FY2026 EPS Estimates for Astrazeneca Cut by Erste Group Bank - MarketBeat
Astrazeneca Plc $AZN Shares Sold by NewEdge Advisors LLC - MarketBeat
AstraZeneca (AZN) Pursues Major Merger with Bristol-Myers Squibb - GuruFocus
How investors killed AstraZeneca’s $400bn megadeal - Financial Times
VELA LARGE CAP PLUS FUND's AstraZeneca PLC(AZN) Holding History - GuruFocus
Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks? - Yahoo Finance
AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 32% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Weekly Recap: Merger talks with Bristol Myers and Imjudo launch in China - TradingView
AstraZeneca PLC (AZN.L) Stock Analysis: Evaluating a 31.83% Potential Upside for Savvy Investors - DirectorsTalk Interviews
Oliver Luxxe Assets LLC Purchases New Position in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca Plc $AZN Shares Sold by FNY Investment Advisers LLC - MarketBeat
Gradient Investments LLC Makes New Investment in Astrazeneca Plc $AZN - MarketBeat
161,624 Shares in Astrazeneca Plc $AZN Acquired by Professional Advisory Services Inc. - MarketBeat
Parallel Advisors LLC Purchases New Position in Astrazeneca Plc $AZN - MarketBeat
Community Trust & Investment Co. Makes New $17.27 Million Investment in Astrazeneca Plc $AZN - MarketBeat
Chesley Taft & Associates LLC Invests $15.41 Million in Astrazeneca Plc $AZN - MarketBeat
Cooper Financial Group Buys New Position in Astrazeneca Plc $AZN - MarketBeat
Assenagon Asset Management S.A. Acquires 422,866 Shares of Astrazeneca Plc $AZN - MarketBeat
Key facts: AstraZeneca PLC (AZN) shares dip; UK adds to Global Talent - TradingView
AstraZeneca PLC : Jefferies reaffirms its Buy rating - marketscreener.com
AstraZeneca PLC Stock 12‑Month Price Target Raised to GBX 16091.9, Implies 36% Upside - TradingView
AstraZeneca PLC Stock 12‑Month Price Target Raised to $216.47, Implies 34% Upside - TradingView
Tlwm Makes New $1.76 Million Investment in Astrazeneca Plc $AZN - MarketBeat
Deal or No Deal, AstraZeneca Stock Is a Bargain - WSJ
180 Wealth Advisors LLC Invests $3.89 Million in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca PLC (AZN) Stock Up 3.8% and Still Undervalued -- GF Score: 83/100 - GuruFocus
AstraZeneca, JLR to Benefit as UK Expands Research Visa Program - Bloomberg.com
CPI | AstraZeneca, Bristol Myers Dismiss Merger Talk Speculation - PYMNTS.com
AstraZeneca climbs Wednesday, outperforms market - MarketWatch
'No discussions' over AstraZeneca-Bristol Myers deal, senior source says - Reuters
Astrazeneca Plc (NYSE:AZN) Plans Dividend of GBP 0.80 - MarketBeat
AstraZeneca PLC (AZN) Stock Forecasts - Yahoo Finance
Brokers split on AstraZeneca merger talk as shares recover some ground - finance.yahoo.com
My AstraZeneca shares just crashed 9.7%! Here’s why I’m NOT selling - The Twelfth Magpie
Hilltop National Bank Buys Shares of 7,577 Astrazeneca Plc $AZN - MarketBeat
Versant Capital Management Inc Acquires New Stake in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca shares slump after $400bn BMS merger rumours - Pharmaceutical Technology
Empowered Funds LLC Sells 15,538 Shares of Astrazeneca Plc $AZN - MarketBeat
AstraZeneca (LSE:AZN) Is In Merger Talks With Bristol Myers For $400 Billion - Yahoo Finance
Is AstraZeneca PLC (AZN) a Bargain After 6.9% Drop? GF Value Says Undervalued - GuruFocus
AstraZeneca Investors See Little Logic in Bristol Tie-Up (2) - Bloomberg Law News
AstraZeneca slides Monday, underperforms market - MarketWatch
REGAstraZeneca PLCAdmission of Further Securities to Trading - TradingView
Basecamp Wealth Advisors LLC Cuts Stock Holdings in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says - Yahoo Finance UK
AstraZeneca is said to have explored Bristol Myers mergerBloomberg - Yahoo Finance Singapore
AstraZeneca slides 7% after report of merger talks with Bristol Myers Squibb - Yahoo Finance Australia
Arkadios Wealth Advisors Cuts Stake in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca (NASDAQ: AZN) gains EU nod for Datroway in metastatic TNBC - Stock Titan
Janus Henderson Group PLC Boosts Stake in Astrazeneca Plc $AZN - MarketBeat
Amundi Raises Stock Holdings in Astrazeneca Plc $AZN - MarketBeat
Judge Dismisses AstraZeneca’s Bid To Stop Maine Pharmacy Law - Bloomberg Law News
AstraZeneca's drug pipeine is splitting opinion among City analysts - Proactive Investors
0.40%
0.39%
자본화:
|
볼륨(24시간):